CorFlow Therapeutics AG ("CorFlow") today announced that the Swiss competent authority, Swissmedic, and the Swiss ethics committee, Swissethics, have approved the company’s MOCA I study, which is a three phased First-in-Man clinical trial.

The first MOCA (Microvascular Obstruction with the CoFITM System Assessment) trial is a multi-center prospective, non-randomized safety and feasibility clinical trial which will assess the CorFlow Controlled Flow Infusion (CoFITM) System in up to 58 heart attack patients. In the first roll-in phase, up to 18 non-acute (NSTEMI) patients will undergo microvascular obstruction (MVO) diagnosis using CorFlow’s dynamic Microvascular Resistance (dMVR) sequence. In phase II, dMVR will be measured in 20 acute (STEMI) patients and the peri-procedural measurements will be correlated with post-procedure magnetic resonance imaging (MRI) which will be assessed by an independent MRI corelab. Finally, in Phase III, 20 STEMI patients will be diagnosed using dMVR measurements and treated using intra-coronary CoFITM delivery of tirofiban followed by a final diagnostic sequence. Tirofiban is a small molecule antiplatelet drug belonging to a class of antiplatelet drugs named glycoprotein IIb/IIIa inhibitors. Again, the dMVR measurements will be correlated with post-procedure MRI and evaluated by the independent corelab.

The MOCA I study will generate important information on the feasibility of detecting, quantifying and treating MVO in acute heart attack patients. CorFlow believes that the study will provide early signs on how controlled infusion of intra-coronary agents can reduce the amount of MVO. Microvascular obstruction has been proven in several larger clinical trials to be an independent predictor for major adverse cardiac events such as heart failure and death.

Esther Gerteis, CorFlow’s VP Medical Affairs, commented: "The MOCA I study is the first study which combines diagnosis and treatment of MVO in acute heart attack patients. We look forward to work with the investigators to gain new insights into this unsolved issue. The ultimate goal for the CorFlow clinical activity is to establish a new approach to diagnose and treat MVO in acute heart attack patients whilst following the PCI workflow."

The first hospital to start enrolling patients will be the University Hospital in Bern (Inselspital) with Prof. Marco Valgimigli as Primary Investigator. Additional sites will start subsequently. The study is funded by CorFlow and through a public grant which the company has been awarded from Innosuisse, the Swiss Innovation Agency.

The CoFITM System is designed to measure the amount of MVO and to treat it while the heart attack patient is still in the catheter laboratory. Furthermore, the proprietary CoFITM System is the only of its kind to combine both MVO diagnosis and therapy while adhering to the current guidelines and workflow for heart attack patients. 

Über die CorFlow Therapeutics AG

CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as heart failure. The CorFlow technologies will enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients. 

Caution: The CorFlow Controlled Flow Infusion (CoFITM) technology is in the early phases of development. It will not be available in Europe, the US or Japan for clinical trials until further notice and is NOT available for sale. This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CorFlow are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, European or US Food and Drug Administration (FDA) approvals of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.

Copyright © 2016 – 2018 CorFlow Therapeutics AG. All rights reserved.

Firmenkontakt und Herausgeber der Meldung:

CorFlow Therapeutics AG
Neuhofstrasse 5A
CH6340 Baar
Telefon: +41 (79) 6062-902
http://corflow-therapeutics.ch

Ansprechpartner:
Jon H. Hoem
CEO & Co-Founder
Telefon: +41 (41) 5445556
E-Mail: jhoem@corflow-therapeutics.ch
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.